# Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients

> **NCT00642928** · PHASE2 · COMPLETED · sponsor: **Bioprojet** · enrollment: 108 (actual)

## Conditions studied

- Excessive Daytime Sleepiness
- Parkinson's Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** BF 2.649 5 mg
- **DRUG:** BF 2.649 10 mg
- **DRUG:** BF 2.649 20 mg
- **DRUG:** BF 2.649 40 mg

## Key facts

- **NCT ID:** NCT00642928
- **Lead sponsor:** Bioprojet
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-03
- **Final completion:** 2009-06
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2012-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00642928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00642928, "Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00642928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*